Comparing the current results to its competitors, Transmedics Group Inc reported Revenue increase in the 2 quarter 2026 by 20.7 % year on year. The sales growth was above Transmedics Group Inc 's competitors' average revenue growth of 13.33 %, achieved in the same quarter.
Transmedics Group Inc 's Comment on Competition and Industry Peers
The company developed the Organ Care System (OCS), an FDA-approved, portable, multi-organ, warm perfusion device. It also established the National OCS Program (NOP) to assist transplant programs in procuring donor organs using the OCS. The company recognizes that numerous U.S. and foreign patents owned by third parties in related fields may present challenges to its technology and products and acknowledges the potential for future patent litigation within the medical device industry.
March 25, 2025
In a crucial development for investors of TransMedics Group, Inc. (NASDAQ: TMDX), the Rosen Law Firm, a leading advocate for investor rights, has issued a reminder to shareholders who purchased securities in the company between February 28, 2023, and January 10, 2025. The firm highlights the importance of the upcoming deadline for lead plaintiffs, set for April 15, 2025, in the ongoing securities class action initiated by the firm.As of the latest reports, TransMedics Group’s share price stands at $71.47, reflecting a performance trajectory that has surpassed the market to a modest degree this month, with a decline of just 3.6%. However, a broader analysis over the past year reveals a more concerning narra...
February 1, 2025
In a timely revelation, TransMedics Group, Inc. (NASDAQ: TMDX) finds itself under the microscope of both the investing community and regulatory scrutiny. The Rosen Law Firm, a prominent global investor rights law firm, has announced an investigation into potential securities claims on behalf of shareholders. The focus of this inquiry centers on allegations that TransMedics may have disseminated materially misleading business information to its investors, raising alarms about the integrity of its financial communications.Despite these emerging concerns, TransMedics has recently reported impressive financial performance that starkly contrasts with the broader industry landscape. In the third quarter of 2024, t...
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Meihua International Medical Technologies Co Ltd Share Performance
-81.83%
This Quarter
Meihua International Medical Technologies Co Ltd
Profile
Meihua International Medical Technologies Co. Limi operates on a business model focused on the development and distribution of medical technologies and solutions. The company aims to deliver innovative and quality medical equipment to healthcare providers and institutions globally. By leveraging their expertise and partnerships, Meihua strives to enhance healthcare outcomes and contribute to the advancement of medical technology.
Inspiremd Inc is a medical device company that develops and commercializes stent systems for the treatment of coronary artery disease. Their business model revolves around the production and distribution of their proprietary stent systems to healthcare providers worldwide.
Orchestra Biomed Holdings Inc is a medical technology company that primarily focuses on the development and commercialization of innovative therapies for cardiac diseases. Their business model revolves around identifying unmet needs in the cardiovascular market, developing novel therapeutic solutions, and bringing them to market through strategic partnerships and collaborations.
Penumbra Inc operates on a business model that focuses on the development and manufacturing of innovative medical devices. They aim to provide cutting-edge technologies and solutions to improve patient outcomes in various medical fields. The company primarily generates revenue through the sales of their medical devices to healthcare professionals and institutions worldwide.
Sources:
Transmedics Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Transmedics Group Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
